

Index

Note: Page numbers followed by “f” and “t” indicate figures and tables respectively

- A**
- Acute myelogenous leukemia (AML), 340
- Adjuvant accelerated partial breast irradiation (ABPI), 225
- Adjuvant hormonal therapy, 225–226
- Adjuvant radiotherapy, 190, 223–225
- Adjuvant systemic therapy, 149, 311, 522
- adjuvant bisphosphonates, 317
 - adjuvant chemotherapy, 312
 - anthracyclines, 312–314
 - single agent or combination chemotherapy, 312
 - taxanes, 314
 - adjuvant endocrine therapy, 315
 - aromatase inhibitors, 315–316
 - aims of, 311
 - cancer stem cells, 311
 - immunogenicity, 312
 - micro-metastatic disease, 311
 - ER- and PR-negative tumour, 524
 - genomic testing, 317–318
 - HER-2 negative tumors, 523
 - HER-2 positive tumors, 523–524
 - monoclonal antibodies, 316–317
 - ovarian suppression, 317
 - treatment benefit, 522
 - treatment selection, 522–523
 - trials in older patients, 318–319
- Adjuvant therapy, 324
- GnRH α for ovarian protection, 326
 - neoadjuvant therapy, 327
 - postmenopausal patients, 328
 - postmenopausal women, 326–327
 - premenopausal patients, 324, 327
 - aromatase inhibitors (AIs), 325–326
 - ovarian function suppression (OFS), 324–325
 - tamoxifen, 324
- Ado-trastuzumab emtansine (T-DM1), 358–359, 397–398, 459
- Afatinib, 354t
- Aflibercept, 362t, 364
- Alkylating agents, 347, 348t
 - bendamustine, 348–349, 348t
 - cyclophosphamide, 347–348, 348t
- Alloplastic vs. autogenous reconstruction
- alloplastic, 276–277
 - implant complications reconstruction, 279–280
 - implant types, 277–278
 - permanent tissue expander, 279
 - single stage reconstruction implants, 278–279
 - two stage expander, 278
- ALTT0 (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) trial, 402
- design of, 441f
- Amastia/athelia, 44, 46
- American Cancer Society (ACS), 147, 632, 637
- American Joint Committee on Cancer (AJCC) staging system, 160
- Anastrozole, 53, 325, 326, 328, 368, 395, 457
- Anatomy and physiology, 2
- factors, 2, 3t, 25, 27
 - gross anatomy
 - changes, lifespan, 6–7
 - lymphatic drainage, 5–6, 7f
 - nerve supply, 4–5
 - relationships and quadrants, 2, 4
 - vascular supply, 5, 6f
 - histology
 - basement membrane (BM), 9, 13
 - 3-D reconstruction, parenchyma, 9
 - lactiferous duct, 5
 - low power micrograph, 8f
 - nipple and areola, 9
 - parenchyma, 9–13
 - stroma, 13–15
 - hormones
 - estrogen and progesterone, 15–17
 - GnRH, 15
 - hypothalamo–hypophyseal–gonadal axis, 16f
 - menstrual cycle, 15, 16f
 - oxytocin (OXT), 17, 27
 - mammary gland-related mouse gene knockouts, 3t
 - mammary gland structure and function
 - adult premenopausal breast, 22–23
 - birth-puberty development, 20
 - lactation, 25–28
 - postlactational involution, 28
 - postmenopausal involution, 28–29
 - pregnancy, 23–25
 - prenatal development, 18–19
 - puberty, 20–22
 - other regulators, breast development, 17–18
- Angiogenesis inhibitors, 417–418
- Angiosarcoma, 190
- Anthracyclines, 312–314, 335
- acute myelogenous leukemia (AML), 340
 - in adjuvant chemotherapy and alternative anthracycline-free regimens, 340–341

- avoiding, 401
 - cardiotoxicity, 339–340
 - chemotherapy, 419
 - liposomal anthracyclines, 341–342
 - myelodysplastic syndromes (MDS), 340
 - Antiangiogenic agents, 359, 361*t*
 - affibercept, 364
 - antiangiogenic tyrosine kinase inhibitors (TKIs), 364
 - sorafenib, 361*t*, 364
 - sunitinib, 361*t*, 364
 - bevacizumab, 359–363, 361*t*
 - ramucirumab, 364–365
 - trebananib, 365
 - VEGF-Trap, 364
 - Antiangiogenic tyrosine kinase inhibitors (TKIs), 364
 - sorafenib, 361*t*, 364
 - sunitinib, 361*t*, 364
 - Antidepressant medications, 569, 570*t*
 - syndromes treated by, 569*t*
 - Antimetabolites, 350, 351*t*
 - capecitabine, 352
 - 5-fluorouracil (5-FU), 352
 - gemcitabine, 352–353
 - methotrexate (MTX), 350
 - Anxiety disorder, 566–567
 - APHINITY trial, 402
 - Architectural distortion, 165
 - Aromatase inhibitors, 315–316, 366–367, 596
 - efficacy, 596
 - side effects, 596–597
 - Aromatase inhibitors (AIs), 325–326, 521, 523
 - Arterial supply, 5
 - Ataxia-telangiectasia (AT), 150
 - Atypical ductal hyperplasia (ADH), 182–183
 - Atypical lobular hyperplasia (ALH), 173, 184
 - Autogenous reconstruction
 - abdominal perforator flaps, 284–285
 - gluteal musculocutaneous and perforator flaps, 286
 - latissimus dorsi musculocutaneous flap, 285–286
 - myocutaneous flaps, 280
 - TRAM flaps, 282
 - bipedicled, 282
 - free, 283–284
 - midabdominal, 283
 - pedicled/unipedicled flap, 281–282, 281*f*, 282*f*
 - Autologous fat grafting, 287
 - Axilla management
 - axillary relapse, 237–238
 - lymph node classification, 236
 - partial ALND, 237
 - radiotherapy, 241
 - skip metastases, 237
 - staging, 238–239
 - survival, 237
 - Axillary dissection, 231, 253, 546
 - Axillary lymph node dissection (ALND), 230, 236–237, 251
 - axillary relapse, 252–253
 - completion, 257–259
 - overall survival, 252
 - partial, 237
 - surgical aspects, 251–252
 - Axillary lymph nodes, anatomy of, 248, 249*f*
 - Axillary node sampling, 253
 - blue dye-assisted node sampling (BDANS), 253–254
 - four-node axillary sampling, 253
- B**
- Bacterial infection of nipple, 97
 - Basal-like subtype, 209
 - biological and epidemiological implications, 210–211
 - Bayesian approach, 610
 - Bazedoxifen, 488–489
 - Beam arrangement for the supraclavicular and axillary apex area, 296*f*
 - Bendamustine, 348–349, 348*t*
 - Bevacizumab, 359–363, 361*t*, 403, 537
 - in neoadjuvant chemotherapy, 445
 - Biomarkers, 195
 - predictive, 195
 - prognostic, 195
 - Bisphosphonates (BPs), 371
 - adjuvant, 317, 374–375
 - nitrogenous, 372–374
 - nonnitrogenous, 372
 - Blue dye-assisted node sampling (BDANS), 247, 253–254
 - Body mass index (BMI), 130
 - Bone metastasis, 463
 - locoregional therapy of, 464–465
 - systemic therapy of, 463–464
 - Bone mineral density (BMD), 146
 - Bone-targeted agents, 371, 372*t*
 - adjuvant use of, 374
 - adjuvant bisphosphonates, 374–375
 - adjuvant denosumab, 375
 - bisphosphonates (BPs), 371
 - nitrogenous bisphosphonates, 372–374
 - nonnitrogenous bisphosphonates, 372
 - rank ligand (RANKL) inhibitors, 374
 - denosumab, 374
 - Brain metastasis, 465
 - general recommendations, 465
 - radiotherapy for, 465–466
 - systemic therapy of, 465
 - Breast cancer
 - aetiology
 - alcohol, 131
 - body fat distribution, 130
 - body mass index (BMI), 130
 - breast density and benign breast disease, 131
 - diet, 131
 - endogenous sex hormones, 130
 - exogenous sex hormones, 131
 - height, 130
 - inheritance, 128–130
 - ionising radiation, 131
 - lifestyle, 131
 - physical activity, 131
 - reproductive factors, 130
 - risk factors, 127–131
 - diagnosis, 531–532
 - epidemiology, 529–530
 - extended family members, 588–589
 - family history, 578–580
 - fertility preservation
 - American Society of Clinical Oncology, 541
 - embryo cryopreservation, 542
 - ovogenesis, 541
 - ovarian tissue cryopreservation, 543
 - fetal exposure, staging procedures
 - axillary dissection, 546
 - chemotherapy, 546–547
 - granulocyte colony-stimulating factor (G-CSF), 548

- mastectomy, 546
- methotrexate avoidance, 548
- pregnancy, surgery safety, 545
- radiation therapy, 546
- genetic testing
 - education and counseling, 582–583
 - interpretation, 583
- high risk gene mutation carriers, medical management of, 585
- high-risk individuals, medical management
 - chemoprevention, 586
 - mutation carriers diagnosis, 588
 - ovarian cancer, screening, 584
 - predisposition gene mutation carriers, 585
 - risk-reducing mastectomy, 587–588
 - risk-reducing salpingo-oophorectomy, 586–587
 - screening, men and women, 584, 585
 - without identifiable mutation, 584
- incidence and mortality rates, 125–127
- lactation
 - BRCA2 mutation, 543
 - fine-needle aspiration (FNA), 544–545
 - gestational/pregnancy-associated breast cancer, 543
 - management/treatment (*see* Lactation)
 - sonography, 544
- management/treatment, 539
- moderate risk gene mutation carriers, medical management of, 585
- monoclonal antibodies, 539
 - vascular endothelial growth factor (VEGF), 537
- PARP1 [poly(ADP-ribose) polymerase-1], 538
- pedigree symbols, 579f
- personal health history, 580
- pregnancy after breast cancer, 549–550
- prevalence, 127
- primary prevention, 131–133
- psychological support
 - anxiety disorder, 566–567
 - cognitive difficulties, 568
 - diagnosis, 565
 - estrogen deficiency and depression, 568–569
 - fatigue, 569
 - hormonal medication adherence, 566
 - hormonal treatment effect, 566
 - insomnia, 567, 567t
 - major depressive disorder (MDD), 569
 - psychotic illness, 570
 - treatment, 569–570
- psychosocial, familial and professional aspects, 550–551
- risk assessment
 - absolute risk, 580
 - BRCA gene mutation, BRCAPro and BOADICEA, 581
 - Gail model and Claus tables, 581
 - relative risk, 580
- risk factors/prognosis
 - BRCA1/BRCA2 mutations, 530
 - fetal estrogen, 531
 - oral contraceptive, 530
- secondary prevention/screening, 133
- side effects
 - radiation therapy, 540–541
 - surgery, 539
 - systemic treatment, 539–540
- somatic and germline genetics, 575–576
- survivors care, 541
- syndromes
 - BRCA1/BRCA2 mutation, 575, 577
 - Li-Fraumeni disorder, 583
 - tumor characteristics, 532–533
 - tyrosine kinase inhibitors, 538
 - vaccines, 538–539
 - 5-year survival, 133
- Breast Cancer Index (BCI), 199
- Breast cancer in males (BCM)
 - associated factors and conditions, 494–496
 - vs. BCF, 504–507
 - breast lump diagnosis, 498
 - factors associated with development of, 495t
 - family history and genetics, 496
 - global distribution, 494
 - histologies, 497
 - imaging, 498
 - physical findings, 498
 - prognostic factors, 503–504
 - staging, 497
 - survivorship issues, 507–508
 - family members, testing of, 507
 - follow-up, 507
 - psychological issues/resources/support groups, 508
 - tumor registry, 507
- treatment and outcomes
 - adjuvant chemotherapy, 502–503
 - hormone therapy, 503
 - palliative therapy, 503
 - prognostic factors, 503–504
 - radiation therapy (RT), 502
 - surgery, 501–502
- tumor biology, 497
- U.S. incidence, 494
- Breast cancer screening
 - benefits, 139, 140t
 - breast self-examination (BSE), 147, 148
 - breast ultrasound, 146
 - clinical breast examination (CBE), 147–148
 - breast cancer detection and demonstration project (BCDDP), 147
 - CNBSS, 147–148
 - mammography screening, 141
 - Canadian trials, 143
 - vs. diagnostic mammography, 141
 - Edinburgh trial, 143
 - effect of age, 145–146
 - health insurance plan (HIP) trial, 142
 - meta-analyses, 144
 - randomized controlled trials characteristics, 142t
 - Swedish trials, 142–143
 - United Kingdom age trial, 143–144
 - MRI, 146–147
 - potential hazards, 149
 - cost, 151–152
 - false positives, 150
 - lead time, 150
 - over-diagnosis, 151
 - radiation exposure, 150–151
 - principles, 139
 - detectable preclinical phase (DPCP), 139–140
 - lead-time bias, 140
 - length and selection bias, 140–141
 - total preclinical phase (TPCP), 139
- Breast cancer screening programs (BSC), 133
- Breast cancer specific survival (BCSS), 198
- Breast center
 - accreditation award matrix, 647
 - breast program staff education, 646
 - center leadership

- cancer conference, 640
- evaluation and management guidelines, 641
- level of responsibility and accountability, 639–640
- responsibility and accountability level, 639–640
- clinical management
 - AJCC staging, 642
 - benign breast disease, evaluation and management, 644
 - breast cancer surveillance, 642
 - breast conservation, 641–642
 - diagnostic imaging, 642–643
 - educational resources, 644
 - genetic evaluation and management, 643–644
 - interdisciplinary patient management, 641
 - medical oncology, 643
 - needle biopsy, 643
 - nursing, 643
 - pathology reports, 642
 - patient navigation, 641
 - radiation oncology, 643
 - reconstructive surgery, 644
 - sentinel node biopsy, 641
 - stereotactic core needle biopsy, 643
 - support and rehabilitation, 643
 - ultrasonography, 643
- community outreach, 645–646
- member organizations, 638*t*
- National Accreditation Program for Breast Centers (NAPBC)
 - accredited center benefits, 647
 - mission objectives, 639, 639*t*
 - standards, 639
- prevention and early detection programs, 646
- quality improvement, 646
- research
 - clinical trial accrual, 645
 - clinical trial information, 645
- survey process, 646–647
- Breast conserving surgery (BCS)
 - appropriate surgical therapy, 234
 - axillary surgery, 236
 - factors, 232
 - frequency, 234
 - ipsilateral breast tumor recurrences, 231
 - preoperative chemotherapy, 234
 - vs. radical mastectomy, 232
 - RT administration, 232
 - tumor size, 233
- Breast-conserving therapy (BCT), 273, 299, 546, 533
- Breastfeeding, benefits of, 81–82
- Breastfeeding and lactation problems
 - intrapartum period, 85
 - galactopoiesis failure, 87
 - hospital discharge planning, 90
 - in-hospital risk assessment, 90
 - lactation establishment, 85
 - lactogenesis failure, 86–87
 - mammogenesis failure, 85–86
 - maternal psychosocial health, 90
 - milk intake, 90
 - milk transfer, 87–89
 - postpartum period, 91
 - clinical breastfeeding assessment, 91
 - insufficient milk syndrome, 92–93
 - maternal hyperlactation syndrome, 93–96
 - medicines, 99
 - relactation, 99
 - sore nipples, 96–98
 - prenatal period, 81
 - anticipatory guidance, 84–85
 - breastfeeding benefits, 81–82
 - infant formula hazards, 82
 - informed choice, 81
 - prenatal breast examination, 84
 - prenatal education, 82
 - prenatal lactation assessment, 82–83
 - screening for risk factors, 83–84
- Breast imaging
 - breast ultrasound
 - cystic masses, 169–170
 - normal anatomy, 169
 - core needle biopsy (CNB), 172
 - indications, relative, contraindications and complications, 173
 - postcore biopsy, 113
 - magnetic resonance imaging, 173–175
 - mammography
 - abnormality location, 163, 164*f*
 - calcifications, 164–165, 166*f*
 - craniocaudal (CC), 157, 158*f*
 - diagnostics, 160
 - false-negative mammograms, 168
 - indirect and secondary signs of malignancy, 165, 167*f*, 168
 - masses, 164
 - mediolateral oblique (MLO), 157, 158*f*
 - report, 161–163
 - screening, potential adverse consequences, 168
 - radionuclide imaging, 175
 - screening, 171–172
 - solid masses, 170–171, 170*f*
 - technical advances, 169
 - ultrasonography, 157
- Breast imaging reporting and data system (BI-RADS), 157, 162–163
- Breast lift procedure, 287
- Breast mass evaluation, 105
 - benign breast masses, 120–121
 - benign nodularity, 121
 - breast sepsis, 122
 - breast ultrasound, 112, 113*f*–114*f*
 - clinical examination, 107–110
 - abnormalities detection, 108
 - bilateral axillary examination, 110
 - inspection and palpation, 108
 - left breast cancer, 110*f*, 112*f*
 - craniocaudal mammograms, 111, 112*f*, 117*f*
 - cysts, 112, 113*f*, 114*f*, 121
 - fat necrosis, 123
 - fibroadenoma, 112, 116*f*, 119
 - history of presentation, 106
 - bleeding nipple discharge, 106, 107*f*
 - features, 106, 106*t*
 - nipple retraction, cancer, 108*f*, 110*f*
 - patient age and diagnosis, 106*t*
 - patient's record, 109*t*
 - skin nodules, 106, 108*f*
 - intraduct papilloma, 122
 - investigation, 110
 - magnetic resonance imaging (MRI), 115–116, 117*f*–118*f*
 - magnification views, 113*f*
 - mammography, 114–115
 - medio-lateral oblique views, 111, 112*f*
 - other lesions, 123
 - pathology diagnosis
 - core needle, fibroadenoma, 119*f*
 - cytology scoring, 118

- fine needle aspiration cytology, 120f
 - malignant cells, 114
 - needle localisation, 120f
 - X-ray image, cores, 119, 119f
- patient plan, 120
- phyllodes tumour, 121
- positron emission tomography/computerised tomography (PET/CT), 116–117
- pregnancy and lactation, 121
- presentation routes, 105
 - incidental detection, 106
 - screening, 106
 - symptomatic, 105–106
- skin lesions, 122
- Breast program leadership (BPL), 639–642
- Breast quadrants, 4, 4f
- Breast reconstructive surgery, 273
 - alloplastic vs. autogenous, 276–280
 - autogenous reconstruction, 280–286
 - chemotherapy, 288
 - indications, 274
 - nipple–areola reconstruction, 286–287
 - radiation, 287–288
 - skin-sparing mastectomy, 274
 - timing, 275–276
- Breast self-examination (BSE), 133
- Breast ultrasound
 - cystic masses, 169–170
 - normal anatomy, 169
 - screening, 171–172
 - solid masses, 170–171, 170f
 - technical advances, 169
- Bromocriptine, 51, 77

- C**
- Calcifications, 164–165, 166f
- Calcium metabolism, during lactation, 27–28
- Canadian National Breast Screening Study (CNBSS), 141, 143, 147–148, 150
- Cancer Chemotherapy National Service Center (CCNSC), 602–603
- The Cancer Genome Atlas (TCGA) Project, 204
- Cancer stem cells, 311
- Candida albicans*, 97
- Candidiasis, 97–98
- Capecitabine, 344, 351r, 352, 362, 394, 397, 462
- Carboplatin, 349–350, 350r, 415–416, 444
- Cardiac events and timing hypothesis, 483–484
- Cardiff Breast Pain Chart, 74f, 77
- Cardiotoxicity, 339–340
- CD8 + T cells, 312
- Chapped nipples, 97
- Chemoprevention of breast cancer, 593
 - chemoprevention agents, 593
 - aromatase inhibitors, 596–597
 - tamoxifen, 593–596
 - prevention trials, 597
 - exemestane, using, 599
 - International Breast Cancer Intervention Study-II, 597–599
 - new agents, 599
- Chemotherapy, adjuvant, 312
 - anthracyclines, 312–314
 - single agent or combination chemotherapy, 312
 - taxanes, 314
- Chemotherapy (CT), 453
- Chest wall tenderness, 75–76, 76f
- Chlorpromazine, 99
- Cisplatin, 349, 350r
- Claudin-low tumors, 211
- Clinical breast examination (CBE), 133
- Clinical trials
 - baseline outcome rates, 612
 - clinical significance vs. statistical significance, 611–612
 - competing risks, design under, 629–630
 - design considerations
 - control group choice, 610
 - definition, 609–610
 - masking and placebos, 610–611
 - precision and eliminating bias, 608–609
 - disease-free survival (DFS), 628
 - ethical concerns, 618
 - evolution, 601–602
 - Food and Drug Administration (FDA), 617
 - fundamental features
 - collaboration, 603–604
 - explanatory and pragmatic considerations, 606–608
 - new drug development and testing, 605
 - primary question selection, 608
 - history of cancer cooperative groups, 602–603
 - intention-to-treat (ITT) analysis, 625
 - interpretation, 630–631
 - Kaplan-Meier life-table, 626
 - 1-KM method vs. nonparametric cumulative incidence approach, 628–629
 - log-rank test, 626
 - loss of power and sample size, 629–630
 - multiplicity considerations, 628
 - multivariable models, 627–628
 - National Institutes of Health (NIH), 616
 - NSABP Biostatistical Center, 625
 - NSABP Protocol B-06
 - data integrity, 620–621
 - ethical controversies, 618
 - Greco-Latin square design, 618–620
 - interim data monitoring, 621–625
 - International Conference on Harmonization (ICH), 622
 - lumpectomy, 618–619
 - manual of operations (MOP), 621
 - prerandomization approach, 619–620
 - population measures of variability, 612
 - prediction model, validation and building, 630
 - randomization methods
 - biased coin algorithm, 615–616
 - phase III cancer trial, 614
 - pseudorandom sequence, 615
 - regression, on cumulative incidence function, 629
 - sample size adjustments, 613
 - statistical analysis, 623
 - statistical inference and sample size considerations, 597–598
 - statistical significance and study power, 612
 - time-to-event outcomes, 612–613
 - two-sample considerations, 629
 - type I (α) and type II (β) error, 612
- Clodronate, 372r, 373
- Cognitive behavioral therapy (CBT), 570
- Cognitive difficulties, 568
- Colloid carcinoma. *See* Mucinous carcinoma
- Comprehensive geriatric assessment (CGA), 525
- Congenital and developmental abnormalities anatomy, 41
 - breast masses
 - biopsy, 41
 - gynecomastia, 52–53

- polymastia/polythelia, 42–43
 - congenital breast hypoplasia/aplasia, 43
 - amastia/athelia, 44, 46
 - Poland syndrome, 46
 - tubular/tuberous breast, 46–49
 - embryonic development, mammary glands, 46
 - gigantomastia, 50, 51–52
 - intrauterine development, 46
 - inverted nipples, 49–52, 50*f*
 - nipple-areolar complex (NAC), 41
 - premature thelarche, 42
 - puberty, 42
 - Conjugated Equine synthetic Estrogen (CEE), 485
 - Connective tissue growth factor (CTGF), 18
 - Consolidated Standards of Reporting Trials (CONSORT) statement, 631
 - Contralateral breast, 287
 - Contralateral breast cancer, 596, 597*f*
 - Contralateral prophylactic mastectomy (CPM), 235
 - Contrast-enhanced breast MRI, 175
 - Cooper's ligament, 42
 - Core needle biopsy (CNB), 172–173
 - Cox proportional hazards model, 627
 - Craniocaudal mammograms, 111, 112*f*, 117*f*
 - Cribriform carcinoma, 188
 - Cyclin-dependent kinases (CDKs), 458
 - Cyclophosphamide, 347–348, 348*t*
 - Cyclophosphamide, methotrexate and 5-fluorouracil (CMF), 312
 - CYP 2D6, 200
 - Cytotoxic agents, systemic therapy, 335
 - alkylating agents, 347, 348*t*
 - bendamustine, 348–349
 - cyclophosphamide, 347–348
 - antimetabolites, 350
 - capecitabine, 352
 - 5-fluorouracil (5-FU), 352
 - gemcitabine, 352–353
 - methotrexate (MTX), 350
 - platinum-based chemotherapeutic agents, 349–350
 - topoisomerase II inhibitors, 335, 336*t*
 - anthracyclines, 335–342
 - tubulin inhibitors, 342
 - epothilones (ixabepilone), 344
 - eribulin, 347
 - taxanes, 342–344
 - vinca alkaloids (vinorelbine), 346–347
- D**
- Danazol, 77
 - Danish Osteoporosis Prevention Study (DOPS), 484
 - Deep circumflex iliac artery (DCIA), 281
 - Deep inferior epigastric (artery) perforator (DIEP), 236
 - flap, 284, 285*f*
 - Deep inspiration breath-hold (DIBH) technique, 295
 - Denosumab, 372*t*, 374, 464
 - Denosumab, adjuvant, 375
 - Department of Defense (DoD) healthcare system, 234
 - Dermatitis of nipple, 98
 - Detectable preclinical phase (DPCP), 139–140
 - Diagnostic mammography, 160
 - Digital breast tomosynthesis (DBT), 157, 160–161
 - Docetaxel, 342, 343, 345*t*
 - Domperidone, 99
 - Dose distribution in the breast, 295*f*
 - Doxorubicin, 314, 318, 336*t*, 339, 341
 - Drug-induced gigantomastia, 51–52
 - Ductal carcinoma
 - cribriform carcinoma, 189
 - Elston–Ellis modification, 189
 - mammography, 64
 - medullary carcinoma, 189
 - metaplastic carcinoma, 189
 - tubular carcinoma, 189
 - variants, invasive breast cancer, 189
 - Ductal carcinoma in situ (DCIS), 151, 179, 180–182, 261, 297–299
 - adjuvant hormonal therapy, 225–226
 - adjuvant radiotherapy, 223–225
 - biology, 221–222
 - breast treatment
 - local recurrence rate, 224–225
 - mastectomy, 222
 - wide local excision, 223
 - diagnosis, 222
 - follow-up, 221, 226
 - grading and risk assessment, 180–181
 - incidence and clinical presentation, 180
 - molecular pathology and special types, 181
 - mortality, 180
 - MRI utility, 222
 - natural history, 180, 221
 - partial breast irradiation, 225
 - pathologic working up of, 182
 - presentation, 222, 225
 - recurrence treatment, 223–224
 - surgery, 222–223
- E**
- Early breast cancer (EBC)
 - decision-making in, 199–200
 - multigene assays in, 196–199, 197*t*
 - therapy concepts in, 196*f*
 - Early Breast Cancer Treatment Collaborative Group (EBCTCG), 631
 - Early Breast Cancer Trialists Collaborative Group (EBCTCG), 232, 312, 521, 522
 - Early stage breast cancer
 - ductal carcinoma in situ, 297–299
 - invasive breast cancer
 - breast-conserving therapy, 299–304
 - contraindications, 300
 - local recurrence, 301
 - mutations, 301
 - neoadjuvant chemotherapy, 305
 - postmastectomy radiation, 302–304
 - radiation and breast reconstruction, 304
 - E-cadherin, 185, 214, 425
 - Edinburgh trial, 143, 147
 - Elderly breast cancer
 - adjuvant systemic therapy
 - ER- and PR-negative tumour, 524
 - HER-2 negative tumors, 523
 - HER-2 positive tumors, 523–524
 - treatment benefit, 522
 - treatment selection, 522–523
 - chemoprevention of breast cancer, 520
 - clinical assessment, 519–520
 - clinical trials, 525
 - epidemiology, 519
 - metastatic disease, 524–525
 - primary breast cancer treatment
 - axilla management, 521–522

- radiation therapy, 521
 - surgery/endocrine therapy, 521
 - screening, 520–521
 - Embryo cryopreservation, 542
 - Endocrine therapy, 323
 - adjuvant therapy, 315, 324
 - aromatase inhibitors, 315–316
 - GnRHa for ovarian protection, 326
 - neoadjuvant therapy, 327
 - postmenopausal women, 326–327, 328
 - premenopausal patients, 324, 327
 - metastatic therapy, 328
 - HR+/HER2+, 330–331
 - postmenopausal patients, 329–330
 - premenopausal patients, 328–329
 - overcoming endocrine resistance, 331–332
 - Endocrine therapy (ET), 365
 - aromatase inhibitors, 366–367
 - combination of endocrine therapies, 368
 - fulvestrant, 367–368
 - gonadotropin-releasing hormone (GnRH) analogs, 368–369
 - selective estrogen receptor modulators (SERMs), 365
 - tamoxifen, 365–366
 - targeted agents used in combination with, 369
 - everolimus, 369
 - palbociclib and Cdk4/6 inhibitors, 370–371
 - PIK3CA inhibitors, 369–370
 - Endogenous sex hormones, 130
 - Endopredict, 198–199
 - English OPTIMA program, 199
 - Eosinophils, 14
 - EPclin, 198
 - Epidermal growth factor receptors (EGFRs), 17
 - Epirubicin, 336*r*
 - Epothilones (ixabepilone), 344
 - EPrognosis website, 519
 - ER+HER2 negative ABC, treatment of, 454
 - biological and endocrine resistance, 457–458
 - chemotherapy, 458
 - endocrine therapy, 454–457
 - Eribulin, 346*t*, 347, 394
 - ER-positive and -negative breast cancer, 534–535
 - Estrogen and breast cancer in postmenopausal women, 475
 - Women's Health Initiative (WHI) HRT trials, 476–477
 - design, 477
 - E + P vs. placebo, 477–478
 - follow-up, 478–480
 - methodology, 480–481
 - Estrogen and cardiac events with all-cause mortality, 483
 - cardiac events and timing hypothesis, 483–484
 - estrogen and biochemical surrogates, 486–488
 - HRT agent selection and cardiac outcome, 484–485
 - HRT and breast cancer patients with BRCA mutations, 489
 - HRT developments, 488
 - tibolone and bazedoxifen, 488–489
 - WHI HRT trials and cardiac outcomes, 485–486
 - Estrogen deficiency and depression, 568–569
 - Estrogen receptor (ER), 12, 15
 - Estrogen receptor cross-talk pathways, 455*f*
 - European Organization for Research and Treatment of Cancer (EORTC), 423, 534
 - Everolimus, 360*t*, 369, 538
 - Exemestane, 360*r*, 599
 - Exogenous sex hormones, 131
 - Exploratory anti-HER2 blockade strategies, 405–406
 - ExteNET, 402
 - Extracellular matrix (ECM), 10, 15
- ## F
- Feedback inhibitor of lactation (FIL), 85
 - Fetal exposure by staging procedures, 545*r*
 - Fibrocystic disease, 61
 - Fine needle aspirate (FNA), 412, 414, 499–501, 500*f*
 - FinHer trial, 400
 - First-line single-agent therapy, 392–393
 - Fluconazole, 98
 - Fluorine-18 2-deoxy-2-fluoro-D-glucose (FDG), 175
 - 5-fluorouracil (5-FU), 351*t*, 352
 - Follicle stimulating hormone (FSH), 15, 27
 - Formalin-fixed paraffin-embedded (FFPE), 198
 - Four-node axillary sampling, 253
 - Frequently mutated genes in breast cancer, 213
 - lobular breast cancer, 214
 - Fulvestrant, 360*r*, 367–368, 455–457
- ## G
- Gail model and Claus tables, 581
 - Galactopoiesis process, 85, 87
 - Galactorrhea, 60, 61*t*
 - Gemcitabine, 351*t*, 352–353, 394
 - 21 Gene Assay, 196–198
 - 70 Gene Assay, 198
 - Gene expression profiling, 204
 - Gene expression vs. histopathology, intrinsic subtyping based on, 205
 - Genome-wide association studies (GWAS), 130
 - Genomic testing, 317–318
 - Gentian violet, 98
 - GeparQuinto study, 403
 - GeparQuinto trial, 417, 418
 - GeparSixto trial, 415
 - GeparTrio study, 416
 - Geriatric assessment (GA), 519–520
 - German GeparQuinto trial, 417, 418
 - Glandular failure, 86
 - GnRHa for ovarian protection, 326
 - Gonadotropin releasing hormone (GnRH), 15, 27, 542
 - analogues, 368–369
 - Goserelin (Zoladex), 77, 360*r*
 - Gravid-induced gigantomastia, 51
 - Gross anatomy
 - changes, lifespan, 6–7
 - lymphatic drainage, 5, 7*f*
 - dye microinjection, 6
 - internal mammary nodes, 5, 6
 - pectoralis major, 5
 - pectoralis minor, 5
 - nerve supply
 - cutaneous and intercostal nerves, 4–5
 - sympathetic fibers, 5
 - relationships and quadrants, 2, 4, 4*f*
 - sagittal section, lactating breast, 4*f*
 - vascular supply, 5, 6*f*
 - Gynecomastia, 52–53, 491–493
 - bilateral, 53*f*
 - causes of, 53*t*
 - conditions associated with, 492*t*
 - drugs associated with, 492*t*

H

‘Halstedian’ hypothesis, 249
 Health insurance plan (HIP) trial, 142, 143, 147
 Hepatic cytochrome P450 2D2, 200
 HER2, 13
 overexpression, 134
 HER+ABC, treatment of, 458
 first-line therapy, 459–461
 progression beyond second line therapy, 462
 second-line therapy, 461–462
 treatment of HER2+/HR+ disease, 462
 unanswered questions for management HER2 positive disease, 462–463
 HERA trial, 399–400
 Hereditary breast cancer, 575
 genes associated with, 576
 predispositions
 high-risk, 577–578
 moderate-risk, 578
 HER2-enriched subtype, 208–209
 HER2-positive breast cancer, 440–441
 High-risk individuals
 chemoprevention, 586
 mutation carriers diagnosis, 588
 ovarian cancer, screening, 584
 predisposition gene mutation carriers, 585
 risk-reducing mastectomy, 587–588
 risk-reducing salpingo-oophorectomy, 586–587
 screening, men and women, 584, 585
 without identifiable mutation, 584
 Hormonal medication adherence, 566
 Hormonal treatment effect, 566
 Hormone receptor positive/human epidermal growth factor receptor 2-positive breast cancer (HR+/HER2+), 330–331
 Hormone replacement therapy (HRT), 131, 475, 481
 Hormone replacement trial
 agent selection and cardiac outcome, 484–485
 and breast cancer patients with BRCA mutations, 489
 developments, 488
 Human chorionic gonadotropin (hCG) hormones, 24–25
 Human epidermal growth factor receptor 2 (HER2)-targeted therapies, 353, 354*t*
 ado-trastuzumab emtansine, T-DM1, 358–359
 lapatinib, 354*t*, 356–357
 new HER2-directed agents and combinations under investigation, 359
 pertuzumab, 354*t*, 357–358
 trastuzumab, 353–356, 354*t*
 Human epidermal growth factor receptor-2 (HER2) targeted therapy, 383–384, 272
 accurate identification, 391
 adjuvant setting, trastuzumab
 anthracyclines, avoiding, 401
 BCIRG 006 trial, 399–400
 combined American NSABP-B31 and NCCTG-N9831 trials, 399, 400
 duration, 400–401
 efficacy in trial, 398–399
 FinHer trial, 400
 HERA trial, 399–400
 safety in trial, 399
 sequencing and timing, 400
 small HER2+ tumors, 401
 ado-trastuzumab emtansine (T-DM1), 397–398
 ASCO/CAP Updated Recommendations, 392
 bevacizumab, 403

dual HER2 targeted therapies, neoadjuvant trials of, 404*t*
 EGFR inhibitors, 382–383
 exploratory anti-HER2 blockade strategies, 405–406
 lapatinib, 402
 metastatic HER2+ breast cancers, algorithm for treating, 398
 first-line therapy, 398
 second-line therapy, 398
 third-line therapy and beyond, 398
 metastatic setting, trastuzumab
 after disease progression, 395
 combination with chemotherapy, 393–394
 combination with hormonal therapy, 394–395
 first-line single-agent therapy, 392–393
 single-agent therapy, 392
 neoadjuvant HER2+ approaches, 403
 lapatinib-based neoadjuvant regimens, 403–405
 neratinib-based neoadjuvant regimens, 405
 pertuzumab-based neoadjuvant regimens, 405
 trastuzumab, neoadjuvant, 403
 neratinib, 402–403
 oncogene hypothesis, 391
 pertuzumab, 402
 4-Hydroxytamoxifen (4-OHT), 77
 Hyperplasia of breast, 50–52

I

Ibandronate, 372*t*, 373
 Immediate reconstruction, 275–276
 Immunogenicity, 312
 Inflammatory and locally advanced breast cancer, 420*f*
 diagnosis and staging, 412–415
 different presentations, 413*f*
 epidemiology, 411–412
 flow diagram describing management of, 429*f*
 local therapy, 421–424
 management, 415, 428
 molecular biology, 424–425
 prognostic factors, 426
 survival, 426–429
 systemic therapy
 anthracycline-based chemotherapy, 419
 immunotherapy, 418
 for inflammatory breast cancer, 418–421
 investigational therapy, 417–418
 neoadjuvant chemotherapy, 415–416
 neoadjuvant endocrine therapy, 417
 and pCR, 418
 preoperative HER2-directed therapy, 416–417
 Inframammary fold (IMF), 275, 277
 Insomnia, 567, 567*t*
 Insufficient milk syndrome, 92–93, 93*f*
 Insulin-like growth factors (IGFs), 17–18
 Integrins, 12, 13, 15
 Intensity-modulated radiation therapy (IMRT), 293
 Intercostobrachial nerve (ICBN), 251
 Interim data monitoring
 breast cancer prevention trial (BCPT), 624
 data monitoring committee (DMC), 622–623
 herceptin, 624
 mechanism, 622
 quality assurance, 622
 statistical methods, 623
 Internal mammary chain (IMC), 249
 Internal mammary node biopsy, 265–266
 Internal mammary nodes (IMN), 296

- International Agency for Research on Cancer (IARC), 133
 International Breast Cancer Intervention Study-II, 597–599
 International (Ludwig) Breast Cancer Study Group (IBCSG), 534
 Intra-operative node assessment, 259–260
 Intrinsic subtypes, main molecular features of, 205
 basal-like subtype, 209
 biological and epidemiological implications, 210–211
 claudin-low tumors, 211
 HER2-enriched subtype, 208–209
 luminal disease, 205–207
 Intrinsic subtypes in metastatic setting, 213
 Intrinsic subtyping based on gene expression vs. histopathology, 205
 Invasive breast cancer
 breast-conserving therapy, 299–304
 contraindications, 300
 local recurrence, 301
 mutations, 301
 neoadjuvant chemotherapy, 305
 postmastectomy radiation, 302–304
 radiation and breast reconstruction, 304
 Invasive carcinoma, 186
 breast cancer classification and grading, 186
 invasive lobular carcinoma (ILC), 186–188
 no special type (NST), 186–187
 sarcoma and malignant phyllodes tumors, 190
 special types, 190
 tumor grading, 190
 Ionizing radiation, 292
 Ipsilateral breast, 231–232
 Ipsilateral breast tumor recurrence (IBTR), 426
 Ixabepilone, 344, 346*r*
- J**
 Japan Strategic Anti-cancer Randomized Trial (J-START), 146
 Juvenile hypertrophy, 50–51
- K**
 Kaplan-Meier survival rate representation, 427*f*
 KATHERINE trial, 418
 King's/Cambridge trials, 230–231
- L**
 Lactation, 81
 calcium metabolism, 27–28
 effects, nursing mother, 27
 events, 25–26
 hormones, 27
 IgA, 26, 27
 lipid droplets, 26
 management/treatment
 breast conserving vs. mastectomy, 533–534
 cellular mechanisms, 536
 chemotherapy, 534–535
 endocrine, 535–536
 radiation, 534
 paracellular pathway, 27
 proteinaceous material, 26
 regulatory factors, 20
 secretory process, 26–27
 Laminin, 10, 13
 Lapatinib, 354*r*, 356–357, 402, 417, 459
 Lapatinib-based neoadjuvant regimens, 403–405
 Lapatinib dual kinase inhibitor, 538
 Letrozol, 326, 328, 360*r*
 Leuprorelin, 360*r*
 Li-Fraumeni syndrome, 496
 Linear accelerator (LINAC), 292*f*
 Liposomal anthracyclines, 341–342
 Liposomal doxorubicin, 336*r*
 Liver metastasis, 466
 Lobular breast cancer, 214
 Lobular carcinoma in situ (LCIS), 173, 183, 184–185, 185*f*
 Lobular neoplasia (LN), 183–185
 Locally advanced breast cancers (LABC), 403
 Local-regional recurrence (LRR), 426
 Locoregional therapy of bone metastases, 464–465
 Loss of heterozygosity (LOH), 214
 Luminal disease, 205–207
 Luminal epithelial cells, 23, 26
 Luminal tumours, 134
 Lumpectomy, 231, 233, 238
 Luteal phase, 22
 Luteinizing hormone (LH), 15, 27
 Lymphatic plexuses, 5
 Lymphatic system of the breast, 248–251
 Lymphedema, 297, 540–541
- M**
 Magnetic resonance imaging (MRI), 115–116, 117*f*, 234, 544
 Major depressive disorder (MDD), 569
 Major histocompatibility complex class 1 (MHC1), 312
 Male breast diseases
 benign breast conditions, 493
 breast cancer
 adjuvant chemotherapy, 502–503
 associated factors and conditions, 494–496
 vs. BCF, 504–507
 family history and genetics, 496
 global distribution, 494
 histologies, 497
 hormone therapy, 503
 imaging, 498
 palliative therapy, 503
 physical findings, 498
 prognostic factors, 503–504
 radiation therapy (RT), 502
 staging, 497
 surgery, 501–502
 survivorship issues, 507–508
 tumor biology, 497
 U.S. incidence, 494
 differential diagnosis of breast masses, 498–501
 gynecomastia, 491–493
 malignant breast conditions in males, 499*r*
 Mammogenesis, 85–86
 Mammography report
 BI-RADS, 161
 breast tissue composition, 162
 final assessment categories, 162–163
 findings, 162
 Manual stripping, 95
 Mastalgia
 breast cancer, 75
 chest wall pain, 74–75
 classification, 73, 74*r*
 clinical assessment and investigations, 75–76
 cyclical mastalgia, 73
 agnus castus, 76

- non-steroidal anti-inflammatory drugs (NSAIDs), 77
 - oral contraceptive method, 76
 - premenstrual syndrome (PMS), 74
 - etiology, 73
 - management algorithm, 77–78
 - non-chest wall pain, 73, 75
 - non-cyclical mastalgia, 73, 77
 - psychosocial factors, 75
 - Mastopexy, 287
 - Maternal hyperlactation syndrome, 93
 - acute mastitis, 94
 - breast abscess, 95
 - chronic mastitis, 94
 - clinical spectrum, 93
 - decreased milk retention, 95
 - infection treatment, 95–96
 - milk stasis, 94
 - milk synthesis, 95
 - obstruction removal, 95
 - recurrence prevention, 96
 - supportive measures, 96
 - white spot, 94
 - Matrix metalloproteinases (MMPs), 10
 - Mediolateral oblique (MLO), 157, 158f
 - Medullary carcinoma, 188
 - Memorial Sloan-Kettering Cancer Center, 502, 505, 507
 - Metaplastic carcinoma, 188
 - Metastatic breast cancer, 451
 - epidemiology, 451
 - future perspectives, 467
 - new biology insights, 451–452
 - role of imaging, nuclear medicine, and other technology, 452
 - supportive care and survivorship issues, 466–467
 - treatment, 452
 - bone metastasis, 463
 - brain metastasis, 465–466
 - of ER+HER2 negative ABC, 454–458
 - general principles, 452–454
 - of HER+ABC, 458–463
 - liver metastasis, 466
 - locoregional therapy of bone metastases, 464–465
 - systemic therapy of bone metastases, 463–464
 - of triple negative ABC, 463
 - Metastatic breast cancer (mBC), 451
 - Metastatic disease, 524–525
 - Metastatic HER2+ breast cancers, algorithm for treating, 398
 - first-line therapy, 398
 - second-line therapy, 398
 - third-line therapy and beyond, 398
 - Metastatic therapy, 328
 - HR+/HER2+, 330–331
 - postmenopausal patients, 329–330
 - premenopausal patients, 328–329
 - Methotrexate (MTX), 350, 351r
 - Metoclopramide, 99
 - Microarray in node-negative disease may avoid chemotherapy trial (MINDACT), 198, 533
 - Microdochestomy, 67
 - Micromastia, 44f, 45f
 - Micro-metastatic disease, 311
 - Micropapillary carcinoma, 189
 - MicroRNAs (MiRNAs), 424–425
 - Milk intake
 - duration and factors, 89, 90
 - frequency, 89
 - pattern, breast usage, 90
 - Milk synthesis, maternal, 92f
 - Milk transfer
 - breastfeeding skills, 88
 - impeding milk transfer, 88–89
 - milk ejection reflex, 87, 88
 - positioning, 88
 - suckling, 88
 - MISCAN (microsimulation screening analysis), 145
 - Mitoxantrone, 336r
 - and other topoisomerase II inhibitors, 341–342
 - Molecular classification of breast cancer, 203
 - frequently mutated genes in breast cancer, 213
 - lobular breast cancer, 214
 - intrinsic subtypes, main molecular features of, 205
 - basal-like subtype, 209–211
 - claudin-low tumors, 211
 - HER2-enriched subtype, 208–209
 - luminal disease, 205–207
 - intrinsic subtypes in metastatic setting, 213
 - intrinsic subtyping based on gene expression vs. histopathology, 205
 - novel subgroups, 212
 - Molecular subtypes in breast cancer and therapy concepts, 195–196
 - Molecular testing for therapy prediction, 200
 - Monoclonal antibodies, 316–317
 - Montgomery's tubercles, 62
 - MTOR inhibitors, 418
 - Mucinous carcinoma, 186r
 - Multifocal and multicentric tumours, 261
 - Multigene assays, 196, 197r
 - clinical use of, 199–200
 - Endopredict, 198–199
 - 21 Gene Assay, 196–198
 - 70 Gene Assay, 198
 - Prosigna (PAM50), 199
 - Multileaf collimator (MLC), 293, 293f
 - Myelodysplastic syndromes (MDS), 340
 - Myocardial infarction (MI), 151
 - Myoepithelial cells, 10–11
- N**
- Nab-paclitaxel, 342, 344, 345r
 - National Accreditation Program for Breast Centers (NAPBC), 637–639
 - accredited center benefits, 647
 - mission objectives, 638
 - standards, 639
 - National Cancer Data Base (NCDB), 501, 502, 637
 - National Cancer Institute (NCI), 415, 602
 - National Surgical Adjuvant Breast and Bowel Project (NSABP), 222, 223, 415, 422, 601, 615
 - National Surgical Adjuvant Breast Project (NSABP), 312
 - National Surgical Adjuvant Breast Project-04 (NSABP-04), 230
 - Neoadjuvant chemotherapy, 262, 415–416
 - noncross-resistant agents, 416
 - platinum agents, 415–416
 - preoperative anthracycline and taxane, 415
 - sentinel lymph node biopsy after, 263–265
 - sentinel lymph node biopsy prior to, 263
 - Neo-adjuvant chemotherapy setting, axillary surgery in, 241–242
 - Neoadjuvant endocrine therapy, 417
 - Neoadjuvant HER2+ approaches, 403
 - lapatinib-based neoadjuvant regimens, 403–405
 - neratinib-based neoadjuvant regimens, 405
 - pertuzumab-based neoadjuvant regimens, 405
 - trastuzumab, neoadjuvant, 403

- NeoAdjuvant Lapatinib and/or Trastuzumab Optimization (NeoALTTO) trial, 404
- Neoadjuvant systemic treatment (NST), 437
- biomarkers in, 438
 - individual molecular biomarkers of resistance, 439
 - tumor cell proliferation, 439
 - tumor-infiltrating lymphocytes, 439
 - choice of chemotherapy regimens in, 439
 - bevacizumab, use of, 533
 - biomarkers for prediction of platinum efficacy in TNBC, 444
 - HER2-positive breast cancer, 440–441
 - patients with TNBC, 441–444
 - indications for, 437
 - neoadjuvant endocrine approaches, 445
 - pathohistological complete remission (pCR), 438
 - definitions of, 438
 - prognostic significance, 438
 - post-neoadjuvant therapy, dynamic biomarkers, and “window studies,” 445–446
 - radiotherapy after, 447
 - surgical considerations in, 446
 - sentinel node biopsy, 446–447
- NeoALTTO trial, 417, 440f
- Neratinib, 402–403, 538
- Neratinib-based neoadjuvant regimens, 405
- Neuregulin, 17
- Neuropeptides, 5
- New drug development and testing
 - phase I trial, 605
 - phase II trial, 605
 - phase III trial, 605
- Nipple and areola, 9
- Nipple aspirate fluid (NAF), 56–57, 57–58, 66
- Nipple discharge
 - algorithm, 69f
 - anatomy and physiology, 57
 - biochemical markers, 66
 - breast cancer, 66, 68
 - characteristics and etiology, 59–63
 - bloody discharge, 62
 - carcinoma, 63
 - cysts communication, 61
 - cytologic evaluation, 62
 - duct ectasia, 61
 - fibrocystic disease, 61
 - galactorrhea, 60, 61t
 - Montgomery’s tubercles, 62
 - nonpathologic nipple discharge, 60
 - opalescent physiologic discharge, 60
 - papillomas, 62
 - pathologic and physiologic nipple discharge, 58
 - cytology, 66–67
 - definition, 57–58
 - diagnostic evaluation, 64
 - ductal imaging, 66–67, 66f
 - follow-up, 68–69
 - incidence, 58–59
 - magnetic resonance imaging (MRI), 65
 - mammary ductoscopy, 67–68
 - mammography, 64
 - occult blood, 65
 - surgical evaluation and treatment, 67
 - ultrasound, 64–65
- Nipple-sparing mastectomy (NSM), 274–275
- Nipple trauma, 96–97
- Nitrogenous bisphosphonates, 372–374
- Non-chest wall pain, 73, 75
- Non-cyclical mastalgia, 73
- Nonnitrogenous bisphosphonates, 372
- Nonpathologic nipple discharge, 60t
- Non-sentinel lymph nodes (NSLN), 254
- Novel subgroups of breast cancer, 212
- NSABP Protocol B-06
 - data integrity, 620–621
 - Greco-Latin square design, 618
 - interim data monitoring, 621–625
 - International Conference on Harmonization (ICH), 622
 - lumpectomy, 618–619
 - manual of operations (MOP), 621
 - prerandomization approach, 619–620
- Nystatin suspension, 98
- O**
- 4-OHT. *See* 4-Hydroxytamoxifen
- Oncogene hypothesis, 391
- OncotypeDx 523
- Oocyte cryopreservation, 542
- Ovarian function suppression (OFS), 324–325
- Ovarian protection, GnRHa for, 326
- Ovarian suppression, 317
- Ovarian tissue cryopreservation, 543
- Overcoming endocrine resistance, 331–332
- Oxford overview analysis, 225
- Oxytocin (OXT), 17, 27
- P**
- Paclitaxel, 342, 345t
 - nab-paclitaxel, 344
- Paget’s disease, 98, 108f, 184
- Palbociclib, 361t
- Palbociclib and Cdk4/6 inhibitors, 370–371
- PAM50, 199
- Pamidronate, 372t, 373
- Papillomas, 62
- Parathyroid hormone-related peptide (PTHrP), 19, 28
- Parenchyma
 - luminal epithelial cells, 9–10
 - myoepithelial cells, 10–11
 - stem cells
 - definitions and terms, 11
 - mammary stem cells, 11–12
 - regulation factors, 12–13
 - structure and function, 11
- PARP-inhibitors, 371
- Partial breast irradiation, 225
- Pathohistological complete remission (pCR), 438
 - definitions of, 438
 - prognostic significance, 438
- Pathological complete response (pCR), 426
 - prognosis in patients who do not achieve, 426
- Pathologic nipple discharge (PND), 58, 59f, 60t, 62t, 64
- P-cadherin, 10
- Pegylated liposomal doxorubicin, 336t
- Perforator flaps, 284
- Pertuzumab, 354t, 357–358, 402, 416, 459, 537
- Pertuzumab-based neoadjuvant regimens, 405
- p53 gene, 425
- Photons, 291
- Phyllodes tumors, 189
- Physiologic nipple discharge, 58, 58f, 60t

- PIK3CA inhibitors, 369–370
 PIK3CA mutations, 200
 p27kip1, 425
 Platinum-based chemotherapeutic agents, 349–350, 350f
 Poland syndrome, 46
 classification, 46f
 Poly (ADP-ribose) polymerase (PARP), 463
 Poly(ADP-ribose) polymerase (PARP) inhibitors, 418
 Polymastia, 42–43, 43f
 Polythelia, 42–43
 Positron emission tomography (PET), 175, 176f, 294
 Postglandular, 86, 87
 Postmastectomy radiation/radiotherapy (PMRT), 276, 287, 288
 Precision and eliminating bias
 random errors, 608
 systematic errors, 608
 Prediction Analysis of Microarray 50 (PAM50), 318
 Predictive markers, 195
 Preglandular, 86, 87
 Pregnancy
 cellular hypertrophy and hyperplasia, 23
 development of breast cancer during, 262
 hormones, 24–25
 lobuloalveolar structure, 23
 luminal cells, 23
 luminal epithelial cells, 23, 26
 other regulatory factors, 25
 Pregnancy-specific mammary nuclear factor (PMF), 86
 Premalignant and malignant breast pathology
 basal phenotype, 188
 HER2, oncogene protein, 185
 invasion and metastases, 188
 invasive carcinoma, 186
 breast cancer classification and grading, 186
 invasive lobular carcinoma (ILC), 186–188
 no special type (NST), 186–187
 sarcoma and malignant phyllodes tumors, 190
 special types, 188
 tumor grading, 190
 lobular carcinoma, 184
 malignant tumors, stroma origin, 190
 premalignant lesions, 179
 atypical ductal hyperplasia (ADH), 182–183
 atypical lobular hyperplasia (ALH), 184
 ductal carcinoma in situ (DCIS), 180–182
 lobular carcinoma in situ (LCIS), 183, 184–185
 Premenstrual syndrome (PMS), 74
 Prenatal breast development
 epithelial ingrowth, 18
 fetal period, 18
 genes, transcription factors and growth factors, 19
 hormonal regulation, 19
 stages, 18
 Prenatal lactation assessment
 anticipatory guidance, 84–95
 prenatal breast examination
 nipple graspability, 84
 size and symmetry, 84
 risk factors, screening
 biological factors, infant and maternal, 83
 psychological, 83
 social, 83–84
 Preoperative HER2-directed therapy, 416–417
 lapatinib, 417
 pertuzumab, 416
 trastuzumab, 416
 Primary invasive breast cancer
 axilla management, 236–239
 breast conserving surgery (BCS), 230
 Halstedian concept, 229
 local recurrences, 231–232
 radiotherapy (RT) techniques, 230
 sentinel lymph node biopsy, 239–242
 surgical options, 232
 appropriate surgical therapy, 234
 breast reconstructive surgery, 235–236
 contralateral prophylactic mastectomy (CPM), 235
 extended tylectomy, 233
 factors, 234f
 mammograms, 234
 nipple-areola complex, 234
 quadrantectomy, 233
 reconstructive surgery, 235–236
 Virchow's hypothesis, 229
 Primary operable breast cancers (POBC), 403
 PROACT trial, 417
 Problem solving mammography. *See* Diagnostic mammography
 Progenitor cells, 11
 Progesterone receptor (PR), 11, 17
 Prognostic markers, 195
 Prolactin (PRL), 17, 27, 85
 Prosigna (PAM50), 199
 Prosthetic reconstruction, 276
 Proton therapy, 295
 Protons, 293
 Provera, 480–481
 Psoriasis, 98
 Puberty
 hormonal regulation, 21–22
 inactive human breast, 21f
 mammary gland duct system, 20
 regulatory factors, 21–22
 terminal end buds (TEBs), 20
 Pygo2, 12

Q
 Quadrantectomy, 233

R
 Radiation oncology
 adverse effects, 295–297
 radiation, surgery and chemotherapy, 293
 radiation therapy, physics, 291–293
 technical aspects, 293–295
 Radical mastectomy, 229–230, 232
 Radioisotope, 257
 Radionuclide imaging, 175
 Radiosurgery, 465
 Radiotherapy, 262
 after neoadjuvant systemic treatment, 447
 Radiotherapy for brain metastases, 465–466
 Raloxifene, 520
 prevention trials using, 596f
 Ramucirumab, 362r, 364–365
 Randomized controlled studies, 159
 Rank ligand (RANKL) inhibitors, 374
 denosumab, 374
 Raynaud's phenomenon, 98
 Residual cancer burden (RCB), 438
 Reverse transcriptase polymerase chain reaction (RT-PCR), 257

- Role of radiotherapy
 early stage breast cancer, 297–304
 locally advanced breast cancer, 304–305
 palliation, 305
 radiation oncology, 291–297
- S**
- Salvage mastectomy, 231
- Sarcoma and malignant phyllodes tumors, 190
- Schonberg index, 519
- Sebaceous glands, 9
- Selective estrogen receptor modulators (SERMs), 131–132, 365, 548
 tamoxifen, 365–366
- Sensory fibers, 5
- Sentinel lymph node biopsy (SLNB), 239–242, 247, 254, 423, 521–522, 546
 after neoadjuvant chemotherapy, 263–265
 vs. axillary lymph node dissection, 240–241
 completion axillary lymph node dissection, 257–259
 indications for, 260
 ductal carcinoma in situ, 261
 elderly patients, 262
 multifocal and multicentric tumours, 261
 pregnancy, 262
 repeat, 262
 prior to neoadjuvant chemotherapy, 263
 technical aspects, 255–257
- Sentinel lymph nodes, 5–6
 sentinel lymphadenectomy, SLNE, 446–447
- “SENTinel Neo-Adjuvant” (SENTINA) study, 242
- Sentinel node biopsy, 446–447
- Serum tumour biomarkers, 452
- Sex hormones
 endogenous, 130
 exogenous, 131
- Sialyl-Lewis X/A-deficient MUC1, 425
- Single-agent therapy, 392
- Single nucleotide polymorphisms, 130
- Skeletal-related events (SREs), 373
- Skin-sparing mastectomy, 274, 275f
- Snoopy-nose deformity, 47
- Society of surgical oncology, 274
- Somatic and germline genetics, 575–576
- Sorafenib, 361*t*, 364
- Sore nipples
 bacterial infection, 97
 candidiasis, 97–98
 chapped nipples, 97
 dermatitis, 98
 nipple trauma, 96–97
 Paget’s disease, 98
 psoriasis, 98
 vasospasm/Raynaud’s phenomenon, 98
- Stage migration effect, 237
- Staphylococcus aureus, 97, 98
- Stem cells
 definitions and terms, 11
 mammary stem cells, 11–12
 regulation factors, 12–13
 structure and function, 11
- Stereotactic radiosurgery (SRS), 465
- Stroma
 adipocytes, 13, 14
 epithelial-stromal interactions, 13
 extracellular matrix (ECM), 14
 fibroblasts, 13–14
 interstitial cell of Cajal (ICC), 14
 macrophages, 13, 14
- Stromal fibronectin, 15
- Subclavian artery supply disruption sequence, 46
- Subcutaneous turnover flaps, 50*f*
- Sunitinib, 361*t*, 364
- Superficial inferior epigastric artery (SIEA) perforator flap, 284–285
- Suppression of ovarian function trial (SOFT), 536
- Systemic therapy, 335
 cytotoxic agents, 335
 alkylating agents, 347–349, 348*t*
 antimetabolites, 350–353
 platinum-based chemotherapeutic agents, 349–350
 topoisomerase II inhibitors, 335–342, 336*t*
 tubulin inhibitors, 342–347
- targeted therapies, 353
 antiangiogenic agents, 359–365
 bone-targeted agents, 371–375, 372*t*
 endocrine therapy (ET), 365–371
 human epidermal growth factor receptor 2 (HER2)-targeted therapies, 353–359
 PARP-inhibitors, 371
- Systemic therapy of bone metastases, 463–464
- Systemic therapy of brain metastases, 465
- T**
- Tamoxifen, 52, 77, 225–226, 324, 360*t*, 365–366, 454–455, 521, 593–596
 breast cancer prevention trials using, 594*t*
- Tangential beam arrangement, 294*f*
- Targeted therapies, 353
 antiangiogenic agents, 359
 aflibercept, 364
 antiangiogenic tyrosine kinase inhibitors (TKIs), 364
 bevacizumab, 359–363
 ramucirumab, 364–365
 trebananib, 365
 VEGF-Trap, 364
- bone-targeted agents, 371, 372*t*
 adjuvant use of bone-targeted agents, 374–375
 bisphosphonates (BPs), 371–374
 rank ligand (RANKL) inhibitors, 374
- endocrine therapy (ET), 365
 aromatase inhibitors, 366–367
 combination of endocrine therapies, 368
 fulvestrant, 367–368
 further targeted agents used in combination with endocrine therapies, 369–371
 gonadotropin-releasing hormone (GnRH) analogs, 368–369
 selective estrogen receptor modulators (SERMs), 365–366
- human epidermal growth factor receptor 2 (HER2)-targeted therapies, 353
 ado-trastuzumab emtansine, T-DM1, 358–359
 lapatinib, 356–357
 new HER2-directed agents and combinations under investigation, 359
 pertuzumab, 357–358
 trastuzumab, 353–356
 PARP-inhibitors, 371
- Taxanes, 314, 342, 393, 548
 docetaxel and paclitaxel, 342
 nab-paclitaxel, 344
- T-DM1 (Trastuzumab Emtansine), 537
- TEACH trial, 402

- Terminal ductal lobular units (TDLUs), 8–9, 9*f*, 57
- Thelarche, 6, 41–42
 premature, 42
- Tibolone, 485, 488–489
- Tietze syndrome, 75
- Tipifarnib, 421
- Tissue growth factor α/β , 20
- Topoisomerase II alpha, 200
- Topoisomerase II inhibitors, 335, 336*r*
 anthracyclines, 335
 acute myelogenous leukemia (AML), 340
 in adjuvant chemotherapy and alternative anthracycline-free regimens, 340–341
 cardiotoxicity, 339–340
 liposomal anthracyclines, 341–342
 myelodysplastic syndromes (MDS), 340
- Total preclinical phase (TPCP), 139
- Touch imprint cytology (TIMC), 260
- Tracer agents, sites of injection of, 256*f*
- Transverse rectus abdominis muscle/myocutaneous (TRAM) flap, 236, 273
- Trastuzumab, 353–356, 354*r*, 416, 459, 548
 adjuvant setting
 anthracyclines, avoiding, 401
 BCIRG 006 trial, 399–400
 combined American NSABP-B31 and NCCTG-N9831 trials, 399, 400
 duration, 400–401
 efficacy in trial, 398–399
 FinHer trial, 400
 HERA trial, 399–400
 safety in trial, 399
 sequencing and timing, 400
 small HER2+ tumors, 401
 combined with EGFR inhibitors, 382–383
 large adjuvant trastuzumab trials
 longer term follow-up from, 400*r*
 reports from, 399*r*
 metastatic setting
 after disease progression, 395
 capecitabine, 394
 combination with hormonal therapy, 394–395
 first-line single-agent therapy, 392–393
 gemcitabine, 394
 platinum salts, 393–394
 polychemotherapy, 394
 single-agent therapy, 392
 taxanes, 393
 vinorelbine, 394
- Trastuzumab, neoadjuvant, 403
- Trastuzumab-Emtansin (T-DM1), 354*r*
- Trebananib, 365
- Triple negative ABC, treatment of, 463
- Triple-negative breast cancer (TNBC), 213, 437, 441–444, 535
- TRYPHAENA trial, 416
- TRYPHENA, 405
- Tubular breast deformity, 47*f*
- Tubulin inhibitors, 342
 epothilones (ixabepilone), 344
 eribulin, 347
 taxanes, 342
 docetaxel and paclitaxel, 342–344
 vinca alkaloids (vinorelbine), 346–347
- Tumor grading, 189–190
- Tumor-infiltrating lymphocytes, 439
- U**
- Ultrasound, 64–65, 112, 113*f*–114*f*
- Ultrasound-guided fine needle aspiration, 64–65
- V**
- Vacuum-assisted biopsies (VAB), 119–120
- Vascular supply, 5, 6*f*
- Vasospasm/Raynaud's phenomenon, 98
- VEGF-Trap, 364
- Venous drainage, 5
- Vinblastine, 346
- Vinca alkaloids (vinorelbine), 346–347
- Vincristine, 346
- Vindesine, 346
- Vinflunin, 346
- Vinorelbine, 346, 346–347, 346*r*, 394
- Virchow's hypothesis, 229
- W**
- WECARE (Women's Environment, Cancer, and Radiation Epidemiology) study, 530
- Witches milk, 60
- WNT-1-induced secreted protein 3 (Wisp 3), 425
- Wnt/ β -catenin signaling, 12
- Women's environment, cancer, and radiation epidemiology (WECARE), 530
- Women's Health Initiative (WHI) HRT trials, 476–477
 design, 477
 E + P vs. placebo, 477–478
 estrogen and invasive breast cancer, 478–480
 methodology, 480–481
- Women's Health Initiative (WHI) trial hormone replacement trial 1, 483
 WHI HRT trials and cardiac outcomes, 485–486
- Z**
- Zoledronate, 372*r*, 373
- Zuska's disease, 61